U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553494) titled 'SLN12140 in Adult Participants With IgA Nephropathy in China' on April 14.
Brief Summary: This study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of SLN12140 at different doses in IgA nephropathy subjects who have previously received standard treatment (the standard treatment drugs allowed in this study include: angiotensin-converting enzyme inhibitors [ACEi], angiotensin II receptor blockers [ARB], and sodium-glucose co-transporter 2 inhibitors [SGLT2i]) but have ...